Pharmaceuticals

Neutropenia Biologic Drug Treatment Market Report 2026: Strategic Insights and Revenue Outlook

February 17, 2026February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the neutropenia biologic drug treatment market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Neutropenia Biologic Drug Treatment Market from 2026 to 2030?

The neutropenia biologic drug treatment market has experienced robust expansion in recent years. Its size is projected to grow from $14.78 billion in 2025 to $15.79 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.8%. The historical growth in this market can be attributed to several factors, including growth in cancer chemotherapy usage, approval of filgrastim-based therapies, rising infection-related hospitalizations, adoption of supportive oncology care, and hospital protocol standardization.

The market for neutropenia biologic drug treatments is projected to experience substantial expansion over the coming years. This market is anticipated to reach $20.88 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.2%. Key factors contributing to this anticipated growth include an expanding oncology patient base, the rising adoption of biosimilars, a growing need for long-acting drug formulations, the broadening of outpatient cancer services, and increased spending on healthcare. Significant trends identified for this period encompass the increased application of G-CSF biologics, the greater uptake of long-acting biologic treatments, advancements in managing chemotherapy-induced neutropenia, an emphasis on biosimilars to reduce costs, and the wider distribution through hospital and oncology pharmacies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3456&type=smp

What Drivers Are Affecting Demand In The Neutropenia Biologic Drug Treatment Market?

The worldwide increase in cancer cases is anticipated to fuel the expansion of the market for neutropenia biologic drugs. A growing incidence of cancer, combined with more individuals opting for chemotherapy, has resulted in a rise in the number of people experiencing neutropenia. For example, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that an estimated 165,000 Australians were newly diagnosed with cancer in 2023, which translates to over 450 cases each day, and approximately 55% of these diagnoses were among males. Therefore, the global escalation in cancer incidence rates is projected to boost demand for the neutropenia biologic drug treatment market in the forthcoming years.

Which Segment Groups Are Influencing The Neutropenia Biologic Drug Treatment Market?

The neutropenia biologic drug treatment market covered in this report is segmented –

1) By Drug Type: Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim

2) By Treatment Type: Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs, Other Treatment Types

3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies

What Long-Term Trends Are Expected To Shape The Future Of The Neutropenia Biologic Drug Treatment Market?

Leading companies in the neutropenia biologic drug sector are developing biosimilars to provide more affordable options compared to existing biologics. Biosimilars are biological medications engineered to be virtually identical to an already authorized reference biologic, sharing comparable safety and efficacy profiles. For example, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical firm, introduced Fylnetra (pegfilgrastim-pbbk). This drug is a biosimilar to Neulasta and is intended for the management and prevention of febrile neutropenia in individuals receiving chemotherapy. It operates by binding to particular receptors on hematopoietic cells, thereby promoting the growth and maturation of neutrophil precursors within the bone marrow. This process leads to increased neutrophil production, vital for combating infections, especially in patients undergoing myelosuppressive chemotherapy, ultimately lowering the occurrence of febrile neutropenia linked to cancer therapies.

Who Are The Primary Competitors In The Global Neutropenia Biologic Drug Treatment Market?

Major companies operating in the neutropenia biologic drug treatment market are Amgen Inc., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Johnson & Johnson, Baxter International Inc., Mylan N.V., Takeda Pharmaceutical Company Limited, Bayer AG, Sun Pharmaceutical Industries Ltd., Lupin Limited, Fresenius SE & Co. KGaA, Kyowa Kirin Co. Ltd., CSL Limited, Dr. Reddy’s Laboratories Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Neutropenia Biologic Drug Treatment Market?

North America was the largest region in the neutropenia biologic drug treatment market in 2025. The regions covered in the neutropenia biologic drug treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Neutropenia Biologic Drug Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3456&type=smp

Browse Through More Reports Similar to the Global Neutropenia Biologic Drug Treatment Market 2026, By The Business Research Company

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Pegfilgrastim Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilars-market

Orthopedic Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/orthopedic-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795